Mice expressing KrasG12D in hematopoietic multipotent progenitor cells develop neonatal myeloid leukemia by Tarnawsky, Stefan P. et al.
The Journal of Clinical Investigation B R I E F  R E P O R T
3 6 5 2 jci.org   Volume 127   Number 10   October 2017
Introduction
Juvenile myelomonocytic leukemia (JMML) is a pediatric myelop-
roliferative neoplasm (MPN) caused by somatic mutations in the 
RAS/MEK/ERK pathway signaling genes, including KRAS, NRAS, 
PTPN11, NF1, and c-CBL (1). These mutations result in a hypersen-
sitivity of hematopoietic progenitors to granulocyte macrophage–
CSF (GM-CSF) and lead to monocytosis, anemia, thrombocyto-
penia, hepatosplenomegaly, and infiltration of peripheral tissues 
with histiocytes (2–4). Compared with other pediatric hematolog-
ic malignancies, the prognosis of patients with JMML is very poor. 
Allogeneic hematopoietic stem cell (HSC) transplantation is the 
only curative therapy, which nonetheless has a 5-year overall sur-
vival rate of only 52% (5).
The majority of JMML cases result from a mutation in a sin-
gle gene (6–8). As such, disease models using the most common 
JMML-initiating mutations have been readily generated (9–11). 
The Mx1Cre KrasG12D mouse was the first conditional animal mod-
el of JMML and continues to be studied extensively (12, 13). How-
ever, these mice succumb with MPN that can be exacerbated by T 
cell leukemia/lymphoma (T-ALL) and that is confounded by non-
hematopoietic KrasG12D expression (14–18). While the use of induc-
ible Mx1Cre serves to limit oncogene expression until after birth, 
in utero KrasG12D expression owing to spontaneous Mx1Cre activity 
was not assessed in this model. Moreover, in utero KrasG12D expres-
sion induced by LysMCre or VavCre led to lung adenocarcinoma 
or prenatal lethality, respectively (19, 20). Thus, existing KrasG12D 
models do not directly address the fetal origin of JMML and do not 
reliably recapitulate the myeloid-restricted nature of the disease.
Converging clinical evidence suggests that the origin of 
JMML is closely associated with fetal development. Patients pres-
ent very young with a median age of less than 2 years, and ret-
rospective analyses indicate that the somatic disease–initiating 
mutation is frequently present at birth (6, 21, 22). Furthermore, 
BM progenitors of most patients exhibit a fetal-like gene expres-
sion signature, which correlates with an inferior prognosis (23). 
These findings strongly implicate a developmental origin of 
JMML and imply that disease-initiating mutations occur within a 
specific spatial and temporal context.
Fetal hematopoietic progenitors are functionally distinct from 
adult progenitors. Murine fetal progenitors have greater engraft-
ment efficiency, biased lineage differentiation, and altered sus-
ceptibility to transformation compared with adult counterparts 
(24–27). Analogous studies in humans showed that fetal and cord 
blood CD34+ cells are more proliferative and have a greater pro-
pensity to form myeloid colonies in methylcellulose culture than do 
adult cells (28, 29). These characteristics of fetal progenitors sug-
gest a mechanism through which they may evoke clinical features 
of JMML when challenged with a somatic oncogenic mutation.
We hypothesized that temporal expression of KrasG12D during 
fetal hematopoiesis that was limited functionally to the hemato-
poietic progenitor population would produce a JMML-like disease. 
Recently, the expression pattern of Flt3Cre has been extensively 
studied using lineage-tracing methods (30–32). Robust Flt3Cre 
activity begins in multipotent progenitors (MPPs) at E10.5 and is 
subsequently observed in more than 90% of mature leukocytes. 
We now demonstrate that KrasG12D is sufficient to produce a peri-
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progenitors from Flt3Cre+ KrasG12D animals demonstrated hyper-
sensitivity to GM-CSF in colony-forming assays, which was cor-
rected by MEK inhibition (Figure 1E and Supplemental Figure 6).
To confirm that the disease in Flt3Cre+ KrasG12D animals was 
initiated in utero and could be propagated autonomously in vivo, 
we transplanted E14.5 fetal liver (FL) cells into adult BoyJ ani-
mals (Figure 2A). Progenitors from mutant donors showed robust 
engraftment and rapidly contributed to monocytosis, anemia, and 
thrombocytopenia (Figure 2, B and C, and Supplemental Figure 
7). Mutant progenitors gave rise to expanded myeloid cell popu-
lations in the BM and spleen, leading to hepatosplenomegaly and 
a median survival of 9 weeks (Figure 2, D–H). In stark contrast to 
other KrasG12D models, primary recipients of Flt3Cre+ KrasG12D pro-
genitors showed no signs of T-ALL (Figure 2I). Upon secondary 
transplantation with 4 × 106 primary BM cells, Flt3Cre+ KrasG12D 
mutant cells engrafted, and 5 of 6 recipients rapidly succumbed 
with monocytosis, splenomegaly, and thymic atrophy (Supple-
mental Figure 8). These findings indicate that temporal expres-
sion of KrasG12D in utero transforms fetal hematopoietic progeni-
tors into transplantable JMML-initiating cells.
We proceeded to analyze the effect of fetal KrasG12D expression 
on the frequency and distribution of HSCs and progenitors. In con-
trast to Mx1Cre+ KrasG12D animals (16), we observed a reduction of 
HSCs (Tomato+ LSK CD150+CD48–) and MPPs (GFP+ LSK CD150–
CD48+) in both the BM and spleen of moribund Flt3Cre+ KrasG12D 
mice (Figure 3A). This reduction corresponded with increased 
quiescence among HSCs in Flt3Cre+ KrasG12D mice (Figure 3B and 
Supplemental Figure 9). These effects were mediated non–cell 
autonomously, since LSL-KrasG12D was not recombined in HSCs 
(Supplemental Figure 10). We proceeded to analyze the progeny of 
Flt3Cre+ KrasG12D progenitors and found that BM cells cultured in 
cytokine-free medium gave rise to histiocytes that expressed CD11c 
natal MPN when expressed in fetal hematopoietic progenitors 
using Flt3Cre and have thereby defined the crucial cellular and 
developmental environment needed to produce authentic fea-
tures of KrasG12D-induced JMML.
Results and Discussion
We mated Flt3Cre+ ROSAmTmG/mTmG studs with dams bearing a con-
ditional Lox-STOP-Lox KrasG12D/+ allele (LSL-KrasG12D/+)to gener-
ate Flt3Cre+ ROSAmTmG/+ LSL-KrasG12D/+ mice (hereafter referred to 
as Flt3Cre+ KrasG12D mice), in which oncogene expression could be 
monitored by a switch from Tomato to GFP expression. Flt3Cre+ 
KrasG12D mutants were born at expected Mendelian ratios and had 
weight gain comparable to that of their littermates until 2 weeks of 
age (Figure 1A and Supplemental Figure 1A; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
JCI94031DS1). Mutants and littermates had equivalent activi-
ty of Flt3Cre, as measured by the percentage of GFP+ cells, and 
LSL-KrasG12D recombination in mutant mice was confirmed by 
PCR (Supplemental Figure 1, B and C). After 2 weeks, Flt3Cre+ 
KrasG12D mice showed progressive weight loss, leukocytosis, ane-
mia, thrombocytopenia, and hepatosplenomegaly and died at a 
median age of 26 days (Figure 1, A–C, Supplemental Figure 2, and 
Supplemental Figure 3). Histological organ examination revealed 
a histiocytic infiltrate in the spleen, liver, lung, and intestines 
(Supplemental Figure 4), and a markedly increased frequency 
of CD11b+Gr1+ cells in the blood, BM, liver, and spleen was con-
firmed by flow cytometry (Figure 1D and Supplemental Figure 5). 
Notably, the frequency of CD3+ T lymphocytes and B220+ B lym-
phocytes was decreased, and Flt3Cre+ KrasG12D mice had an atro-
phied thymus compared with that seen in the littermates (Figure 
1D, Supplemental Figure 3, and Supplemental Figure 4C). Consis-
tent with a faithful model of hyperactive RAS-induced JMML, BM 
Figure 1. Flt3Cre+ KrasG12D mice develop a JMML-like disease. (A) Weight gain from birth (n = 12 mutants and 19 controls). (B) Overall survival (statistical 
analysis by Mantel-Cox test). (C) Peripheral blood smear (n = 5). Scale bar: 100 μm. (D) Flow cytometric quantification of tissue leukocytes. (E) Seven-day 
BM colony formation with 100 nM PD0325901 or 0.1% DMSO (n = 3 biological replicates/group). All analyses were performed on 3- to 4-week-old moribund 
Flt3Cre+ KrasG12D mice and age-matched littermates. *P < 0.05, #P < 0.01, and §P < 0.001, by unpaired, 2-tailed Student’s t test (A, D, and E).
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enhanced myeloid cell production compared with adult progeni-
tors targeted by Mx1Cre (24, 27). This context emulates studies of 
JMML patients that highlighted the fetal origins of this disease: the 
causative somatic mutation commonly occurs before birth, and BM 
cells have a gene expression signature that is characteristic of fetal 
progenitors (22, 23). Therefore, in contrast to Mx1Cre, Flt3Cre tar-
gets KrasG12D expression to hematopoietic progenitors at the appro-
priate developmental stage to recapitulate the origin of JMML.
The identity of the JMML-initiating cell has been controver-
sial. On the one hand, case reports have shown that CD34+CD38– 
phenotypic HSCs express disease-initiating mutations (6, 35) 
and that xenotransplantation of patients’ progenitors gives rise to 
mutated myeloid, B, and T cells with a common clonal origin (36). 
On the other hand, circulating T lymphocytes from most patients 
do not express the disease-initiating mutation (7, 37), suggesting 
that JMML is initiated within a MPP that undergoes a differenti-
ation block during T lymphocyte commitment. Consistent with 
this hypothesis, case reports suggest that patients with JMML have 
decreased T cell frequencies in the BM and spleen (38, 39). These 
findings parallel our Flt3Cre+ KrasG12D model, which has a paucity of 
T cells, an atrophied thymus, and abnormal T cell differentiation.
An earlier study found similarly skewed T lymphocyte devel-
opment when KrasG12D expression was restricted to DCs in p53–/– 
mice (40). Our results advance these findings to show that KrasG12D 
expression in multipotent progenitors results in widespread tis-
sue infiltration with DCs that are distinct from the concomitantly 
and CD135 (Supplemental Figure 11). This finding is reminiscent 
of reports describing DC-like tumor cells in patients with JMML 
(2, 33, 34) and prompted us to analyze DC populations in Flt3Cre+ 
KrasG12D animals. We observed a marked increase in the frequen-
cy of CD11c + cells in the BM and spleen (Figure 3C). Strikingly, the 
CD11c+ cell expansion was particularly prominent in the atrophied 
thymus, where we saw a concomitant deficit of CD4–CD8–CD25+ 
committed T cell progenitors and CD4+CD8+ double-positive cells 
(Figure 3, C–F, and Supplemental Figure 12). We also observed this 
propensity for preferential DC differentiation in recipients of Flt-
3Cre+ KrasG12D FL progenitors (Supplemental Figure 13).
We present the first KrasG12D model to our knowledge to uni-
fy JMML disease–defining features: an in utero origin; viability at 
birth followed by a failure to thrive; anemia; thrombocytopenia; 
monocytosis; hepatosplenomegaly; and infiltration of tissues with 
histiocytes. All Flt3Cre+ KrasG12D mice succumbed to a myeloid dis-
ease that could be recapitulated following FL transplantation. This 
is in contrast to existing KrasG12D models, whose MPN is exacerbat-
ed by nonhematopoietic oncogene expression and by the unpre-
dictable coemergence of T-ALL (15–20).
Flt3Cre has an expression pattern markedly different from that 
of Mx1Cre, which may explain the observed respective myeloid ver-
sus lymphoid disease outcomes. Mx1Cre is used to target adult pro-
genitors, whereas Flt3Cre becomes active in fetal MPPs. As such, 
Flt3Cre initiates KrasG12D expression within an in utero progenitor 
that is more proliferative, has greater repopulating ability, and has 
Figure 2. Fetal Flt3Cre+ KrasG12D progenitors initiate a JMML-like disease upon transplantation. (A) Schematic of FL transplants (n = 12 mutant and 8 con-
trol recipients). Analysis of donor cell (B) engraftment and (C) myeloid contribution in peripheral blood. (D and E) Flow cytometric quantification of donor 
leukocytes in BM and spleens of moribund mutant recipients and control recipients 16 weeks after transplantation. max, maximum. (F) Overall survival 
following transplantation (statistical analysis by Mantel-Cox test). (G–I) Normalized tissue weights of analyzed animals. *P < 0.05, #P < 0.01, and  
§P < 0.001, by unpaired, 2-tailed Student’s t test (B–E and G–I).
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lates underappreciated features of JMML such as a paucity of 
mature T lymphocytes and an expansion of DCs and thereby hints 
at potential new therapeutic strategies. Flt3Cre+ KrasG12D mice will 
prove useful for preclinical drug studies targeting the RAS/MEK/
ERK signaling pathway and will help elucidate the developmental 
origins of JMML and pediatric leukemias.
Methods
Detailed methods, including all flow cytometry antibodies (Supple-
mental Table 1), are described in the Supplemental Methods. 
Study approval. Animal studies were approved by the IACUC of the 
Indiana University School of Medicine. Animals were genotyped using 
primers outlined in Supplemental Table 2 of Supplemental Methods.
Statistics. P values comparing mutant and littermate groups were 
calculated using 2-tailed Student’s t tests, Mantel-Cox log-rank tests, 
or χ2 tests, as indicated in the figure legends. P values of less than 0.05 
were considered significant. All error bars represent the SEM.
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A unique feature of Flt3Cre+ KrasG12D mice is that their HSCs do 
not express the oncogene (Supplemental Figure 10). The full pene-
trance of a MPN in our model is therefore consistent with the hypoth-
esis that the HSC is the cell of origin for KrasG12D-evoked T-ALL (16, 
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Flt3Cre KrasG12D mice demonstrates a profound non–cell-auton-
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In summary, we describe what to our knowledge is the first 
KrasG12D mouse model that recapitulates defining features of 
JMML. Flt3Cre+ KrasG12D mice are viable, develop monocytosis, 
anemia, thrombocytopenia, and hepatosplenomegaly and die 
from a fully penetrant myeloid disease. This model further emu-
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gating is shown in Supplemental Figure 9. (C) Flow cytometric quantification of tissue DCs. (D–F) Flow cytometric quantification and representative gating 
of thymic cells. Error bars represent the SEM. Cell-cycle statistical analyses were performed using a χ2 test, and other analyses were performed using an 
unpaired, 2-tailed Student’s t test. *P < 0.05, #P < 0.01, and §P < 0.001.
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